Starts 01/2019 Council

 

The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.

Topics


  • Discovery and evaluation of diets as well as individual dietary factors, natural products and other chemopreventive agents for the prevention of cancer; design, development and synthesis of cancer preventive agents
  • Studies on mechanisms of nutritional prevention at the biochemical, molecular and cellular levels; effects of dietary factors and natural products on hormonal carcinogenesis, chemical carcinogenesis, differentiation/trans-differentiation, apoptosis, metabolome, and cell signaling pathways; the role of diet and natural products in oxidative stress, antioxidant defense mechanisms, and epigenetics
  • Studies on obesity-associated cancer risks and development of preventive approaches to stop, or delay initiation and progression of obesity-related cancers
  • Design and development of approaches to the prevention of tumors via other factors, such as exercise, diet restriction, or vaccines
  • Studies on the relationship of human microbiome and metabolome with cancer and development of novel strategies for prevention of cancer initiation and progression based on microbiome and metabolome profiles
  • Development and validation of biomarkers important in cancer prevention including biomarkers of cancer risk, initiation and progression as well as cancer prevention relevant biomarkers identified via profiling of microbiome and metabolome
  • Preclinical prevention studies including in vitro and in vivo evaluation of efficacy and safety as well as in vitro and in vivo pharmacokinetic and pharmacodynamic studies of dietary, natural, and other chemopreventive agents; Phase I and Phase-II clinical trials of cancer preventive agents

Shared Interests and Overlaps

There are shared interests with Cancer Etiology Study Section (CE) related to chemical carcinogenesis and diet in oxidative stress. Applications aiming to determine how to prevent carcinogenesis and cancer progression using diet, antioxidants or other chemical interventions should be assigned to CPSS. Applications aiming to investigate how chemical carcinogenesis and oxidative stress initiate carcinogenesis should be assigned to CE.

There are shared interests with Cancer Biomarkers Study Section (CBSS) related to cancer biomarkers. Applications dealing with development and validation of biomarkers important in prevention, including markers of cancer risk and progression; understanding the human microbiome's and metabolome’s relationship with cancer and developing novel cancer associated biomarkers and strategies for prevention of cancer initiation and progression, including those based on microbiome and metabolome profiles, should be assigned to CPSS. Applications developing and validating biomarkers of early cancer detection, progression, recurrence, and response to therapy should be assigned to CBSS.

There are shared interests with Tumor Cell Biology Study Section (TCB) related to mechanisms of cancer cell signaling. Applications aiming to understand and to interfere with pro-tumorigenic cell signaling and to augment tumor- suppressor signaling with the goal to prevent cancer initiation and progression should be assigned to CPSS. Applications aiming to investigate signal transduction mechanisms in neoplastic cells, and regulation of tumor cell phenotype and behavior, and tumor progression should be assigned to TCB.

There are shared interests with Mechanisms of Cancer Therapeutics-1 (MCT1) related to investigation of anti-cancer agents. Applications that address nutrition, dietary, natural products, and other chemopreventive factors, and their use in intervention for cancer risk, and inhibition of cancer progression should be assigned to CPSS. Applications aiming to investigate anti-neoplastic agents, mechanisms of resistance to anti-neoplastic agents and methods to circumvent drug resistance should be assigned to MCT1.

There are shared interests with Mechanisms of Cancer Therapeutics-2 (MCT2) related to discovery of new anti-cancer agents. Applications focusing on discovery and evaluation of diets as well as individual dietary factors, natural products and other chemopreventive agents for the prevention of cancer initiation and progression as well as on design, development and synthesis of cancer preventive agents should be assigned to CPSS. Applications that are focused on the discovery, identification and validation of new druggable targets for cancer, and the mechanisms of action of molecular- and genetic-based targeted cancer therapies should be assigned to MCT2.

There are shared interests with Developmental Therapeutics (DT) related to experimental therapeutics. Applications that address development of nutrition, dietary, and chemopreventive factors (including natural products), and their use in intervention for cancer risk and inhibition of cancer progression should be assigned to CPSS. Applications addressing the experimental therapy of neoplastic diseases and developing novel therapeutic strategies should be assigned to DT.

There are shared interests with Cancer Immunopathology and Immunotherapy (CII) related to tumor vaccines. Applications focusing on design and development of vaccines for the prevention of tumors should be assigned to CPSS. Applications focusing on tumor vaccines of all types and dendritic cell-based therapies to induce or amplify tumor immunity should be assigned to CII.

There are shared interests with Gastrointestinal Mucosal Pathobiology (GMPB) related to microbiota. Applications focusing on understanding the human microbiome's relationship with cancer and on developing novel cancer associated biomarkers and strategies for prevention of cancer initiation and progression, including those based on microbiome and metabolome profiles, should be assigned to CPSS. Applications aiming to study the effect of the gastrointestinal microbiota on gastrointestinal health and disease should be assigned to GMPB.

There are shared interests with study sections of Endocrinology, Metabolism, Nutrition and Reproductive Sciences IRG (EMNR) IRG related to obesity. Applications aiming to understand obesity-associated cancer risks and developing preventive approaches to stop, or delay initiation and/or progression of obesity-related cancers should be assigned to CPSS. Applications investigating causes and treatment of obesity should be assigned to EMNR IRG.